Payment overview · 2025
General Payments
$2,241.72
144 reported records · 21 companies
Healthcare provider profile · identity verified
Patrick J Rose, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT CLAIR, MO · NPI 1811208341
Verified facts
What the public records show
CMS Open Payments records show Patrick J Rose, M.D. received $2,241.72 in general payments during 2025 across 144 reported records.
ABBVIE INC. accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Prolia, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $449.04 | 20.0% | 30 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.57 | 10.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $208.82 | 9.3% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $177.61 | 7.9% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $160.69 | 7.2% | 19 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $157.80 | 7.0% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.89 | 6.5% | 16 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $103.67 | 4.6% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $92.62 | 4.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.50 | 4.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.96 | 3.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $65.50 | 2.9% | 4 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $61.76 | 2.8% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.96 | 2.6% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.38 | 1.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $30.85 | 1.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $27.51 | 1.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.93 | 0.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.36 | 0.7% | 1 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $14.94 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.36 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,241.72 | 144 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $239.43 | 18 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $209.13 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $177.61 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $167.59 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $157.80 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $155.08 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $154.44 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $146.89 | 16 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $138.72 | 17 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $138.72 | 17 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $103.67 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $96.60 | 7 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $92.62 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $92.50 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $76.00 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $65.50 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.24 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.19 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $57.96 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.89 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.19 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.90 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.38 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $30.85 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $27.51 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.97 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 82 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 401 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 155 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 266 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 129 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 224 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 28 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 162 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
155 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
82 | 81 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
162 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
129 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
141 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
224 | 54 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
401 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1685 | 462 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1067 | 179 |
| Lisinopril | Lisinopril | 876 | 227 |
| Omeprazole | Omeprazole | 834 | 218 |
| Levothyroxine Sodium | Levothyroxine Sodium | 793 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 750 | 210 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 747 | 191 |
| Tramadol Hcl | Tramadol Hcl | 673 | 137 |
| Alprazolam | Alprazolam | 643 | 113 |
| Gabapentin | Gabapentin | 581 | 166 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 493 | 69 |
| Losartan Potassium | Losartan Potassium | 462 | 137 |
| Pantoprazole Sodium | Pantoprazole Sodium | 435 | 108 |
| Metformin Hcl | Metformin Hcl | 419 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 402 | 109 |
| Eliquis | Apixaban | 401 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 371 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 365 | 112 |
| Furosemide | Furosemide | 359 | 90 |
| Metoprolol Tartrate | Metoprolol Tartrate | 327 | 89 |
| Trazodone Hcl | Trazodone Hcl | 307 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 300 | 114 |
| Famotidine | Famotidine | 296 | 70 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 291 | 82 |
| Oxycodone Hcl | Oxycodone Hcl | 290 | 37 |
| Potassium Chloride | Potassium Chloride | 288 | 66 |
| Zolpidem Tartrate | Zolpidem Tartrate | 288 | 61 |
| Jardiance | Empagliflozin | 266 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 249 | 62 |
| Simvastatin | Simvastatin | 249 | 66 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 248 | 60 |
| Metformin Hcl Er | Metformin Hcl | 238 | 69 |
| Carvedilol | Carvedilol | 225 | 61 |
| Ozempic | Semaglutide | 224 | 54 |
| Finasteride | Finasteride | 221 | 48 |
| Tizanidine Hcl | Tizanidine Hcl | 220 | 57 |
| Pregabalin | Pregabalin | 212 | 47 |
| Sertraline Hcl | Sertraline Hcl | 202 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 54 |
| Buspirone Hcl | Buspirone Hcl | 182 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 182 | 54 |
| Diazepam | Diazepam | 181 | 40 |
| Montelukast Sodium | Montelukast Sodium | 181 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 179 | 46 |
| Allopurinol | Allopurinol | 178 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 178 | 56 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 48 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 162 | 42 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 160 | 33 |
| Farxiga | Dapagliflozin Propanediol | 155 | 29 |
| Baclofen | Baclofen | 153 | 34 |
| Spironolactone | Spironolactone | 147 | 29 |
| Lorazepam | Lorazepam | 144 | 31 |
| Trulicity | Dulaglutide | 141 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 67 |
| Alendronate Sodium | Alendronate Sodium | 133 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 36 |
| Ezetimibe | Ezetimibe | 130 | 35 |
| Mounjaro | Tirzepatide | 129 | 20 |
| Ondansetron Odt | Ondansetron | 127 | 33 |
| Testosterone Cypionate | Testosterone Cypionate | 122 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 121 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 119 | 41 |
| Meloxicam | Meloxicam | 116 | 36 |
| Lovastatin | Lovastatin | 115 | 32 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 113 | 28 |
| Clonazepam | Clonazepam | 113 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 112 | 34 |
| Mirtazapine | Mirtazapine | 111 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 107 | 40 |
| Terazosin Hcl | Terazosin Hcl | 106 | 19 |
| Glimepiride | Glimepiride | 99 | 30 |
| Atenolol | Atenolol | 97 | 26 |
| Bupropion Xl | Bupropion Hcl | 96 | 34 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 96 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 92 | 18 |
| Warfarin Sodium | Warfarin Sodium | 86 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 83 | 21 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 82 | 81 |
| Naproxen | Naproxen | 81 | 17 |
| Prednisone | Prednisone | 81 | 45 |
| Levetiracetam | Levetiracetam | 80 | 13 |
| Nystatin | Nystatin | 76 | 34 |
| Sumatriptan Succinate | Sumatriptan Succinate | 75 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 74 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 74 | 14 |
| Donepezil Hcl | Donepezil Hcl | 71 | 14 |
| Glipizide | Glipizide | 66 | 22 |
| Nabumetone | Nabumetone | 65 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 64 | 20 |
| Celecoxib | Celecoxib | 64 | 21 |
| Clonidine Hcl | Clonidine Hcl | 63 | 16 |
| Ibuprofen | Ibuprofen | 61 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 58 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 58 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 45 |
| Xarelto | Rivaroxaban | 57 | 11 |
| Topiramate | Topiramate | 56 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 22 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 49 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 49 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 49 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 48 | 20 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Myrbetriq | Mirabegron | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 37 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | 15 |
| Doxepin Hcl | Doxepin Hcl | 47 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 13 |
| Nitroglycerin | Nitroglycerin | 45 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 38 |
| Tresiba Flextouch U-100 | Insulin Degludec | 45 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 44 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 44 | 12 |
| Hydrocortisone | Hydrocortisone | 43 | 15 |
| Propranolol Hcl | Propranolol Hcl | 42 | 11 |
| Bumetanide | Bumetanide | 41 | 13 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Linzess | Linaclotide | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 40 | suppressed |
| Cimetidine | Cimetidine | 38 | suppressed |
| Belsomra | Suvorexant | 37 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 16 |
| Varenicline Tartrate | Varenicline Tartrate | 36 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 31 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Cephalexin | Cephalexin | 30 | 24 |
| Ketoconazole | Ketoconazole | 30 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 28 | suppressed |
| Insulin Lispro | Insulin Lispro | 28 | suppressed |
| Prolia | Denosumab | 28 | 19 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 11 |
| Folic Acid | Folic Acid | 24 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 24 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Asa-Butalb-Caffeine-Codeine | Codeine/Butalbital/Asa/Caffein | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Methadone Hcl | Methadone Hcl | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 14 |
| Triazolam | Triazolam | 16 | suppressed |
| Azathioprine | Azathioprine | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Risperidone Odt | Risperidone | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,241.72 · 144 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, JOURNAVX, Kerendia, LOREEV XR, MAVYRET, MOUNJARO, MOVANTIK, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error